These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 27647859)

  • 21. The cost of illness analysis of inflammatory bowel disease.
    Pakdin M; Zarei L; Bagheri Lankarani K; Ghahramani S
    BMC Gastroenterol; 2023 Jan; 23(1):21. PubMed ID: 36658489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidemiological, Clinical, Patient-Reported and Economic Burden of Inflammatory Bowel Disease (Ulcerative colitis and Crohn's disease) in Spain: A Systematic Review.
    Barreiro-de Acosta M; Molero A; Artime E; Díaz-Cerezo S; Lizán L; de Paz HD; Martín-Arranz MD
    Adv Ther; 2023 May; 40(5):1975-2014. PubMed ID: 36928496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data.
    Long GH; Tatro AR; Oh YS; Reddy SR; Ananthakrishnan AN
    Adv Ther; 2019 Nov; 36(11):3079-3095. PubMed ID: 31562607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic analysis of annual health resource utilization and costs in hospitalized patients with inflammatory bowel disease in Switzerland.
    Schoepfer A; Vavricka SR; Brüngger B; Reich O; Blozik E; Bähler C
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):868-875. PubMed ID: 29757772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study.
    Burisch J; Vardi H; Schwartz D; Friger M; Kiudelis G; Kupčinskas J; Fumery M; Gower-Rousseau C; Lakatos L; Lakatos PL; D'Incà R; Sartini A; Valpiani D; Giannotta M; Arebi N; Duricova D; Bortlik M; Chetcuti Zammit S; Ellul P; Pedersen N; Kjeldsen J; Midjord JMM; Nielsen KR; Winther Andersen K; Andersen V; Katsanos KH; Christodoulou DK; Domislovic V; Krznaric Z; Sebastian S; Oksanen P; Collin P; Barros L; Magro F; Salupere R; Kievit HAL; Goldis A; Kaimakliotis IP; Dahlerup JF; Eriksson C; Halfvarson J; Fernandez A; Hernandez V; Turcan S; Belousova E; Langholz E; Munkholm P; Odes S;
    Lancet Gastroenterol Hepatol; 2020 May; 5(5):454-464. PubMed ID: 32061322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease.
    Severs M; Oldenburg B; van Bodegraven AA; Siersema PD; Mangen MJ;
    J Crohns Colitis; 2017 Mar; 11(3):289-296. PubMed ID: 27571772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Out-of-pocket Cost Burden in Pediatric Inflammatory Bowel Disease: A Cross-sectional Cohort Analysis.
    Sin AT; Damman JL; Ziring DA; Gleghorn EE; Garcia-Careaga MG; Gugig RR; Hunter AK; Burgis JC; Bass DM; Park KT
    Inflamm Bowel Dis; 2015 Jun; 21(6):1368-77. PubMed ID: 25839776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A retrospective, case-control study on traditional environmental risk factors in inflammatory bowel disease in Vukovar-Srijem County, north-eastern Croatia, 2010.
    Vcev A; Pezerovic D; Jovanovic Z; Nakic D; Vcev I; Majnarić L
    Wien Klin Wochenschr; 2015 May; 127(9-10):345-54. PubMed ID: 25821054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia.
    AlRuthia Y; Almadi M; Aljebreen A; Azzam N; Alsharif W; Alrasheed H; Almuaythir G; Saeed M; HajkhderMullaissa B; Alharbi O
    J Med Econ; 2020 Oct; 23(10):1102-1110. PubMed ID: 32619388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Duration of smoking cessation in patients with inflammatory bowel disease.
    González-Muñoza C; Gely C; Gordillo J; Bertoletti F; Giordano A; López-Faba A; García-Planella E
    Gastroenterol Hepatol; 2024; 47(6):591-597. PubMed ID: 37977427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Healthcare resource utilization and treatment costs of Finnish chronic inflammatory bowel disease patients treated with infliximab
    Ylisaukko-Oja T; Torvinen S; Ventola H; Schmidt S; Herrala S; Kononoff J; Voutilainen M
    Scand J Gastroenterol; 2019 Jun; 54(6):726-732. PubMed ID: 31203693
    [No Abstract]   [Full Text] [Related]  

  • 32. Sleep disturbance and risk of active disease in patients with Crohn's disease and ulcerative colitis.
    Ananthakrishnan AN; Long MD; Martin CF; Sandler RS; Kappelman MD
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):965-71. PubMed ID: 23376797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey.
    Gunnarsson C; Chen J; Rizzo JA; Ladapo JA; Lofland JH
    Dig Dis Sci; 2012 Dec; 57(12):3080-91. PubMed ID: 22790905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estimation of quality of life in Cypriot patients with inflammatory bowel disease.
    Tsoukka M; Jelastopulu E; Lavranos G; Charalambous G
    World J Gastroenterol; 2017 Jan; 23(1):121-126. PubMed ID: 28104987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Smoking is associated with risk for developing inflammatory bowel disease including late onset ulcerative colitis: a prospective study.
    Salih A; Widbom L; Hultdin J; Karling P
    Scand J Gastroenterol; 2018 Feb; 53(2):173-178. PubMed ID: 29262738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The economic and quality-of-life burden of Crohn's disease in Europe and the United States, 2000 to 2013: a systematic review.
    Floyd DN; Langham S; Séverac HC; Levesque BG
    Dig Dis Sci; 2015 Feb; 60(2):299-312. PubMed ID: 25258034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sex-Related Differences in Patients With Inflammatory Bowel Disease: Results of 2 Prospective Cohort Studies.
    Severs M; Spekhorst LM; Mangen MJ; Dijkstra G; Löwenberg M; Hoentjen F; van der Meulen-de Jong AE; Pierik M; Ponsioen CY; Bouma G; van der Woude JC; van der Valk ME; Romberg-Camps MJL; Clemens CHM; van de Meeberg P; Mahmmod N; Jansen J; Jharap B; Weersma RK; Oldenburg B; Festen EAM; Fidder HH
    Inflamm Bowel Dis; 2018 May; 24(6):1298-1306. PubMed ID: 29688413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inflammatory Bowel Diseases (Crohn´s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications.
    Kostić M; Djakovic L; Šujić R; Godman B; Janković SM
    Appl Health Econ Health Policy; 2017 Feb; 15(1):85-93. PubMed ID: 27587010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phenome-Wide Analysis of Healthcare Costs Associated with Inflammatory Bowel Diseases.
    Cai W; Cagan A; He Z; Ananthakrishnan AN
    Dig Dis Sci; 2021 Mar; 66(3):760-767. PubMed ID: 32436120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Work losses related to inflammatory bowel disease in Canada: results from a National Population Health Survey.
    Longobardi T; Jacobs P; Wu L; Bernstein CN
    Am J Gastroenterol; 2003 Apr; 98(4):844-9. PubMed ID: 12738466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.